Urologic Oncology: Seminars and Original Investigations This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling
AKR1C3, as a crucial androgenic enzyme, facilitates intratumoral androgen biosynthesis and androgen receptor activation in castration-resistant prostate cancer (PCa). The data has shown that AKR1C3 expression is significantly elevated in clinical metastatic PCa specimens, indicating a potential role of AKR1C3 in PCa metastasis. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - August 20, 2018 Category: Urology & Nephrology Authors: Bin Wang, Yanan Gu, Ke Hui, Jun Huang, Shan Xu, Shiqi Wu, Lei Li, Jinhai Fan, Xinyang Wang, Jer-Tsong Hsieh, Dalin He, Kaijie Wu Tags: Original article Source Type: research

Predicting the tumorigenic phenotype of human bladder cancer cells by combining with fetal rat mesenchyme
Most bladder cancers are urothelial carcinomas. Roughly 75% of patients have nonmuscle invasive bladder cancer (NMIBC) and the remainder have muscle invasive or metastatic disease [1]. For all stages, the 5-year relative survival is around 70% to 80% [2]. The rate of recurrence in NMIBC ranges from 50% to 90%. In addition, 10% to 30% of NMIBC patients progress to muscle invasive bladder cancer (MIBC) requiring radical surgery [1]. In NMIBC patients after first transurethral resection, identification of the key predictors of progression should improve overall survival by supporting the use of aggressive treatment in short-t...
Source: Urologic Oncology: Seminars and Original Investigations - August 20, 2018 Category: Urology & Nephrology Authors: Manabu Miki, Kenichiro Ishii, Takeshi Sasaki, Manabu Kato, Shinya Kajiwara, Hideki Kanda, Kiminobu Arima, Yoshifumi Hirokawa, Masatoshi Watanabe, Yoshiki Sugimura Tags: Original Article Source Type: research

Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis
With an estimated 79,030 new diagnoses and 16,870 deaths in 2017, bladder cancer is the 5th most common cancer in the U.S. and conveys the highest mortality among urological malignancies [1]. Despite the significant improvement seen in cancer survival over the last three decades, racial disparities are persistent and most pronounced in Black (non-Hispanic) men and women [2]. Black patients as compared to White (non-Hispanic) patients exhibit half the bladder cancer incidence but show significantly greater mortality. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - August 20, 2018 Category: Urology & Nephrology Authors: Philipp Gild, Stephanie A. Wankowicz, Akshay Sood, Nicolas von Landenberg, David F. Friedlander, Shaheen Alanee, Felix K.H. Chun, Margit Fisch, Mani Menon, Quoc-Dien Trinh, Joaquim Bellmunt, Firas Abdollah Tags: Original Article Source Type: research

Health-related quality of life among elderly Americans diagnosed with upper tract urothelial carcinoma
Outcomes of cancer research are usually described in relation to cancer recurrence, progression, and/or patient survival. These outcomes are essential; however, they may not capture the full impact of cancer on patient's functioning and social well being, especially in elderly patients [1]. Elderly cancer patients are usually under-represented in clinical trials [2]. There are growing reports that in a significant proportion of the elderly cancer population, maintaining an adequate quality of life is more important than length of life [3]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - August 19, 2018 Category: Urology & Nephrology Authors: Mohamed Kamel, Naleen Raj Bhandari, Rodney Davis, Nalin Payakachat Tags: Original Article Source Type: research

The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era
Renal cell carcinoma (RCC) has an estimated 63,990 new cases and 14,400 deaths in 2017 [1]. While the RCC survival rate had been traditionally poor, the 5-year survival rate had increased from 57% in 1987 to 1989 to 74% in 2006 to 2012 [1]. This improvement is likely due to 2 main factors: first is the diffuse use of imaging studies which resulted in increased detection of early-stage disease [2,3]; the other is the targeted therapy (TT) era for advanced RCC beginning at the end of 2005 with 7 antiangiogenic drugs and 2 mammalian target of rapamycin inhibitors approved from 2005 to 2016 by the Food and Drug Administration ...
Source: Urologic Oncology: Seminars and Original Investigations - August 18, 2018 Category: Urology & Nephrology Authors: Yu-Wei Chen, Moshe C. Ornstein, Laura S. Wood, Kimberly D. Allman, Allison Martin, Jennifer Beach, Timothy Gilligan, Jorge A. Garcia, Brian I. Rini Tags: Clinical-Kidney cancer Source Type: research

Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma
Several molecular targeted agents have been approved since 2008 for the treatment of advanced renal cell carcinoma (RCC) in Japan and include vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin inhibitors. These therapeutic agents have prolonged the survival of patients with RCC. However, most patients treated with molecular targeted agents will ultimately acquire resistance to these agents, resulting in disease progression. Many potential prognostic and predictive molecular biomarkers have now been identified in RCC, although none has yet entered clinical practice [1]. (Source: U...
Source: Urologic Oncology: Seminars and Original Investigations - August 18, 2018 Category: Urology & Nephrology Authors: Kosuke Ueda, Shigetaka Suekane, Hirofumi Kurose, Katsuaki Chikui, Makoto Nakiri, Kiyoaki Nishihara, Mitsunori Matsuo, Akihiko Kawahara, Hirohisa Yano, Tsukasa Igawa Tags: Original article Source Type: research

Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment —Analyses from the German clinical RCC-Registry
Although renal cell carcinoma (RCC) represents only approximately 4% of adult malignancies in Europe, it displays the highest mortality rate of all urologic tumors with 40% of RCC patients dying from the disease [1]. In Germany, about 15,100 people are expected to be diagnosed with RCC in 2018 and an estimated 5,400 patients will die of kidney cancer each year [2]. As RCC does not immediately lead to clinical symptoms, about 20% to 30% of RCC patients present with advanced or metastatic disease (mRCC) at diagnosis [3] and about 20% of patients diagnosed with localized disease will subsequently develop metastases [4,5]. (So...
Source: Urologic Oncology: Seminars and Original Investigations - August 18, 2018 Category: Urology & Nephrology Authors: Peter J. Goebell, Lothar M üller, Andreas Hübner, Hanns-Detlev Harich, Emil Boller, Michaela Koska, Martina Jänicke, Norbert Marschner, the RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma) Tags: Original article Source Type: research

Dietary patterns and health-related quality of life in bladder cancer survivors
Society and medicine are placing an increasing emphasis on cancer survivorship [1]. As the population continues to age and cancer treatment evolves, the number of cancer survivors is expected to increase. Greater numbers will then be faced with the physical and psychosocial challenges of recovering from cancer and its treatment [2,3]. This population is already known to have elevated risks of mortality and chronic health conditions [4]. Thus, it is important to align our goals of increased overall and cancer-specific survival with concomitant efforts to improve and optimize quality of life. (Source: Urologic Oncology: Semi...
Source: Urologic Oncology: Seminars and Original Investigations - August 17, 2018 Category: Urology & Nephrology Authors: Ajay Gopalakrishna, Andrew Chang, Thomas A. Longo, Joseph J. Fantony, Michael R. Harrison, Paul E. Wischmeyer, Brant A. Inman Tags: Original article Source Type: research

Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer
Risk-stratification for localized prostate cancer remains challenging, in part due to the heterogeneous nature of the disease [1]. Determining the optimal treatment course for an individual patient requires accurate staging and appropriate risk-stratification to balance treatment efficacy with unwanted side effects. Traditional clinical risk features such as Gleason score, prostate-specific antigen (PSA) level, and clinical stage aid in this process, however significant variability in prognosis remains. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - August 16, 2018 Category: Urology & Nephrology Authors: Greg Kauffmann, Fauzia Arif, Pritesh Patel, Aytek Oto, Stanley L. Liauw Tags: Original Article Source Type: research

Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis
Prostate cancer (CaP) is a heterogeneous disease with high variability in regards to clinical outcome and therapeutic response. While some men will develop an indolent CaP not affecting life expectancy, others might die of CaP. Thus, the process of screening and diagnosing, as well as the therapeutic options and monitoring can be difficult for the urologist —to distinguish between lethal and indolent CaP still remains a challenge. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - August 14, 2018 Category: Urology & Nephrology Authors: In ês Anselmo da Costa, Jörg Hennenlotter, Viktoria Stühler, Ursula Kühs, Marcus Scharpf, Tilman Todenhöfer, Arnulf Stenzl, Jens Bedke Tags: Original article Source Type: research

Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research
Translational medicine (TM) components of prospective clinical trials provide an invaluable opportunity to test hypotheses that contribute to our knowledge of human disease biology and/or the mechanism of action of a given therapeutic intervention. Our ability to sample tumors and their microenvironment, and the depth and breadth of biological information that can be extracted from them, has increased exponentially in recent years. This information is critical to guide the next steps clinical research if we are to accelerate the pace of progress in cancer treatment. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - August 13, 2018 Category: Urology & Nephrology Authors: Joshua J. Meeks, Amir Goldkorn, Ana M. Aparicio, David J. McConkey Tags: Seminars article Source Type: research

Robotic versus open partial nephrectomy for highly complex renal masses: Comparison of perioperative, functional, and oncological outcomes
Considerable evidence suggests that partial nephrectomy (PN) for localized renal cell carcinoma has equivalent oncological outcomes when compared to radical nephrectomy [1,2]. Another unique feature of PN over radical nephrectomy relates to better renal functional preservation, which may confer a lower risk of cardiovascular disease, translating into better overall survival [3]. Various surgical approaches for PN have been described, including open (OPN) and minimally invasive techniques, namely laparoscopic (LPN) and the robot-assisted (RAPN). (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - August 9, 2018 Category: Urology & Nephrology Authors: Juan Garisto, Riccardo Bertolo, Julien Dagenais, Daniel Sagalovich, Khaled Fareed, Amr Fergany, Robert Stein, Jihad Kaouk Tags: Original article Source Type: research

Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation
Prostate cancer (CaP) in men represents the main cancer cause of years lost due to disabilities in most European countries [1]. Theoretically, focal therapy of CaP enables both cancer control and low treatment related side effects, leading to a reduction of years lost due to disabilities. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - August 6, 2018 Category: Urology & Nephrology Authors: Jost von Hardenberg, Niklas Westhoff, Daniel Baumunk, Daniel Hausmann, Thomas Martini, Alexander Marx, Stefan Porubsky, Martin Schostak, Maurice Stephan Michel, Manuel Ritter Tags: Original article Source Type: research

Cover 2 -- Masthead
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - August 1, 2018 Category: Urology & Nephrology Source Type: research

Editorial Board
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - August 1, 2018 Category: Urology & Nephrology Source Type: research